180 related articles for article (PubMed ID: 26439129)
1. A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18-40 Year Old Subjects with Diagnosed Atopic Dermatitis.
Greenberg RN; Hurley MY; Dinh DV; Mraz S; Vera JG; von Bredow D; von Krempelhuber A; Roesch S; Virgin G; Arndtz-Wiedemann N; Meyer TP; Schmidt D; Nichols R; Young P; Chaplin P
PLoS One; 2015; 10(10):e0138348. PubMed ID: 26439129
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis.
von Sonnenburg F; Perona P; Darsow U; Ring J; von Krempelhuber A; Vollmar J; Roesch S; Baedeker N; Kollaritsch H; Chaplin P
Vaccine; 2014 Sep; 32(43):5696-702. PubMed ID: 25149431
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial.
Overton ET; Lawrence SJ; Wagner E; Nopora K; Rösch S; Young P; Schmidt D; Kreusel C; De Carli S; Meyer TP; Weidenthaler H; Samy N; Chaplin P
PLoS One; 2018; 13(4):e0195897. PubMed ID: 29652929
[TBL] [Abstract][Full Text] [Related]
4. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
Greenberg RN; Hay CM; Stapleton JT; Marbury TC; Wagner E; Kreitmeir E; Röesch S; von Krempelhuber A; Young P; Nichols R; Meyer TP; Schmidt D; Weigl J; Virgin G; Arndtz-Wiedemann N; Chaplin P
PLoS One; 2016; 11(6):e0157335. PubMed ID: 27327616
[TBL] [Abstract][Full Text] [Related]
5. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
Walsh SR; Wilck MB; Dominguez DJ; Zablowsky E; Bajimaya S; Gagne LS; Verrill KA; Kleinjan JA; Patel A; Zhang Y; Hill H; Acharyya A; Fisher DC; Antin JH; Seaman MS; Dolin R; Baden LR
J Infect Dis; 2013 Jun; 207(12):1888-97. PubMed ID: 23482644
[TBL] [Abstract][Full Text] [Related]
7. Safety, immunogenicity, and surrogate markers of clinical efficacy for modified vaccinia Ankara as a smallpox vaccine in HIV-infected subjects.
Greenberg RN; Overton ET; Haas DW; Frank I; Goldman M; von Krempelhuber A; Virgin G; Bädeker N; Vollmar J; Chaplin P
J Infect Dis; 2013 Mar; 207(5):749-58. PubMed ID: 23225902
[TBL] [Abstract][Full Text] [Related]
8. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
Parrino J; McCurdy LH; Larkin BD; Gordon IJ; Rucker SE; Enama ME; Koup RA; Roederer M; Bailer RT; Moodie Z; Gu L; Yan L; Graham BS;
Vaccine; 2007 Feb; 25(8):1513-25. PubMed ID: 17126963
[TBL] [Abstract][Full Text] [Related]
9. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
10. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.
Kennedy JS; Greenberg RN
Expert Rev Vaccines; 2009 Jan; 8(1):13-24. PubMed ID: 19093767
[TBL] [Abstract][Full Text] [Related]
11. Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.
Knitlova J; Hajkova V; Voska L; Elsterova J; Obrova B; Melkova Z
PLoS One; 2014; 9(12):e114374. PubMed ID: 25486419
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.
Cosma A; Nagaraj R; Staib C; Diemer C; Wopfner F; Schätzl H; Busch DH; Sutter G; Goebel FD; Erfle V
AIDS Res Hum Retroviruses; 2007 Jun; 23(6):782-93. PubMed ID: 17604541
[TBL] [Abstract][Full Text] [Related]
13. Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.
Frey SE; Winokur PL; Salata RA; El-Kamary SS; Turley CB; Walter EB; Hay CM; Newman FK; Hill HR; Zhang Y; Chaplin P; Tary-Lehmann M; Belshe RB
Vaccine; 2013 Jun; 31(29):3025-33. PubMed ID: 23664987
[TBL] [Abstract][Full Text] [Related]
14. IMVAMUNE, an attenuated modified vaccinia Ankara virus vaccine for smallpox infection.
Jones T
Curr Opin Mol Ther; 2008 Aug; 10(4):407-17. PubMed ID: 18683106
[TBL] [Abstract][Full Text] [Related]
15. Cardiac safety of Modified Vaccinia Ankara for vaccination against smallpox in a young, healthy study population.
Zitzmann-Roth EM; von Sonnenburg F; de la Motte S; Arndtz-Wiedemann N; von Krempelhuber A; Uebler N; Vollmar J; Virgin G; Chaplin P
PLoS One; 2015; 10(4):e0122653. PubMed ID: 25879867
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.
Jackson LA; Frey SE; El Sahly HM; Mulligan MJ; Winokur PL; Kotloff KL; Campbell JD; Atmar RL; Graham I; Anderson EJ; Anderson EL; Patel SM; Fields C; Keitel W; Rouphael N; Hill H; Goll JB
Vaccine; 2017 Mar; 35(13):1675-1682. PubMed ID: 28256358
[TBL] [Abstract][Full Text] [Related]
17. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.
Frey SE; Wald A; Edupuganti S; Jackson LA; Stapleton JT; El Sahly H; El-Kamary SS; Edwards K; Keyserling H; Winokur P; Keitel W; Hill H; Goll JB; Anderson EL; Graham IL; Johnston C; Mulligan M; Rouphael N; Atmar R; Patel S; Chen W; Kotloff K; Creech CB; Chaplin P; Belshe RB
Vaccine; 2015 Sep; 33(39):5225-34. PubMed ID: 26143613
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine.
Vollmar J; Arndtz N; Eckl KM; Thomsen T; Petzold B; Mateo L; Schlereth B; Handley A; King L; Hülsemann V; Tzatzaris M; Merkl K; Wulff N; Chaplin P
Vaccine; 2006 Mar; 24(12):2065-70. PubMed ID: 16337719
[TBL] [Abstract][Full Text] [Related]
19. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.
Wilck MB; Seaman MS; Baden LR; Walsh SR; Grandpre LE; Devoy C; Giri A; Kleinjan JA; Noble LC; Stevenson KE; Kim HT; Dolin R
J Infect Dis; 2010 May; 201(9):1361-70. PubMed ID: 20350191
[TBL] [Abstract][Full Text] [Related]
20. Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial.
Overton ET; Stapleton J; Frank I; Hassler S; Goepfert PA; Barker D; Wagner E; von Krempelhuber A; Virgin G; Meyer TP; Müller J; Bädeker N; Grünert R; Young P; Rösch S; Maclennan J; Arndtz-Wiedemann N; Chaplin P
Open Forum Infect Dis; 2015 Apr; 2(2):ofv040. PubMed ID: 26380340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
